Jacobs Levy Equity Management, Inc Kal Vista Pharmaceuticals, Inc. Transaction History

Jacobs Levy Equity Management, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$6.3 - $8.39 $439,500 - $585,303	69,762 New	69,762 $548,000
Q2 2021 Aug 16, 2021	SELL	$23.12 - $29.91 $1.1 Million - $1.43 Million	-47,681 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$14.69 - $42.57 $85,143 - $246,735	-5,796 Reduced 10.84%	47,681 $1.23 Million
Q4 2020 Feb 16, 2021	BUY	$12.88 - $19.47 $243,625 - $368,275	18,915 Added 54.73%	53,477 $1.02 Million
Q3 2020 Nov 16, 2020	BUY	$9.83 - $13.99 $181,206 - $257,891	18,434 Added 114.3%	34,562 $435,000
Q2 2020 Aug 17, 2020	BUY	$6.75 - $12.89 $108,864 - $207,889	16,128 New	16,128 $195,000

125

47.8M

551K

110K

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $250M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.